Search

Displaying results 6781 - 6790 of 10000 in total
  1. Drug

    Kitasamycin

    go.drugbank.com/drugs/DB09309
    Experimental

    Kitasamycin is a macrolide antibiotic derived from <em>Streptomyces kitasatoensis</em>.

  2. Drug

    Egaptivon pegol

    go.drugbank.com/drugs/DB05202
    Investigational

    Egaptivon pegol, formerly known as ARC1779, is a therapeutic aptamer antagonist of the A1 domain of von Willebrand Factor (vWF), the ligand for receptor glycoprotein 1b on platelets.

  3. Drug

    Fosifloxuridine nafalbenamide

    go.drugbank.com/drugs/DB14859
    Investigational

    Fosifloxuridine nafalbenamide is under investigation in clinical trial NCT03428958 (A Safety Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment).

  4. Drug

    Ieramilimab

    go.drugbank.com/drugs/DB16419
    Investigational

    Ieramilimab is under investigation in clinical trial NCT02460224 (Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.).

  5. Drug

    Neisseria meningitidis group A capsular polysaccharide tetanus toxoid conjugate antigen

    go.drugbank.com/drugs/DB15680
    ApprovedInvestigational

  6. Drug

    Neisseria meningitidis group C capsular polysaccharide tetanus toxoid conjugate antigen

    go.drugbank.com/drugs/DB15681
    ApprovedInvestigational

    Products: NeisVac-C Injektionssuspension in einer Fertigspritze
  7. Drug

    Quavonlimab

    go.drugbank.com/drugs/DB16422
    Investigational

    Quavonlimab is under investigation in clinical trial NCT03179436 (Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)).

  8. Drug

    Nilvadipine

    go.drugbank.com/drugs/DB06712
    Approved

    Nilvadipine is a calcium channel blocker (CCB) for the treatment of hypertension.

  9. Drug

    Abdavomeran

    go.drugbank.com/drugs/DB15695
    Investigational

    [L15012] BNT162b1 is undergoing further evaluation in clinical trials in both the USA (NCT04368728) and Germany (NCT04380701). … [L15007, L15012] Early results from a phase 1/2 study in 45 healthy adult volunteers demonstrated RBD-binding immunoglobulin levels and 50% serum neutralizing titers higher than those observed in [COVID

  10. Drug

    Reposal

    go.drugbank.com/drugs/DB13805
    Experimental

    Reposal is a barbiturate derivative invented in the 1960s in Denmark that has sedative, hypnotic and anticonvulsant properties. It was used primarily in the treatment of insomnia.